Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 2Liver Neoplasms 2Weight Loss 1Primary Graft Dysfunction 1Peripheral Nervous System Diseases 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Muscular Atrophy 1Lymphoma, Non-Hodgkin 1Liver Failure, Acute 1Liver Failure 1Liver Diseases 1Hodgkin Disease 1Hearing Loss 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1

Interventions

TH 302 2pasireotide 1omburtamab I-131 1gallium Ga 68 dotatate 1entinostat 1Thalidomide 1Sunitinib 1Radiotherapy, Image-Guided 1Nivolumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Acetylcysteine × Gastrointestinal × Clear all
NCT02094625 2023-04-18

NAC to Prevent Cisplatin-induced Hearing Loss

Children's Hospital Los Angeles

Phase 1 Completed
52 enrolled
GastrointestinalSarcoma

Liver Neoplasms, Osteosarcoma, Neuroectodermal Tumors, Primitive, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡